Adjuvant treatment of high-risk adult soft tissue sarcomas: A survey by the Italian Sarcoma Group

Tumori

Volumn 92, Issue 2, 2006, Pages 92-97

  Frustaci, Sergio ^a   Berretta, Massimiliano ^a   Comandone, Alessandro ^b   Bidoli, Ettore ^a   De Paoli, Antonino ^a   Gherlinzoni, Franco ^c   De Pas, Tommaso ^d   Barbieri, Enza ^e   Pertici, Maurizio ^f   Apice, Gaetano ^g   Picci, Piero ^h  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b GRADENIGO HOSPITAL   (Italy)

^c General Hospital   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f UNIVERSITY OF FLORENCE   (Italy)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Adjuvant chemotherapy; Adult soft tissue sarcomas; Italian Sarcoma Group; Survey

Indexed keywords

EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN ANTAGONIST; ANTINEOPLASTIC AGENT; PROTECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ALOPECIA; ANEMIA; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG RESPONSE; FEMALE; FOLLOW UP; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; REPRODUCIBILITY; REVIEW; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ARTICLE; BLOOD TRANSFUSION; CANCER STAGING; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG ADMINISTRATION; FEASIBILITY STUDY; HEMATOLOGIC DISEASE; ITALY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SARCOMA; SURVIVAL;

ADOLESCENT; ADULT; AGED; ALOPECIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD TRANSFUSION; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC DISEASES; HUMANS; IFOSFAMIDE; ITALY; MALE; MESNA; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROTECTIVE AGENTS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SARCOMA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33744770580     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160609200202     Document Type: Review

References (16)

1. Zalupski MM, Ryan JR, Hussein M: Defining the role of adjuvant chemotherapy for patients with soft tissue sarcoma of the extremities. In: Adjuvant therapy of cancer, Salmon SE (Ed), VII, pp 385-392, JB Lippincott, Philadelphia, 1993.
2. Jones GW, Chouinard M, Patel M: A systematic overview and quantitative meta-analysis. Clin Invest Med, 14: A772, 1991.
3. Tierney JF, Mosseri V, Stewart LA, Souhami RL, Parmar MKB: Adjuvant chemotherapy for soft-tissue sarcoma: review and metaanalysis of the published results of randomized clinical trials. Br J Cancer, 72: 469-475, 1995.
4. Sarcoma Meta-analysis Collaboration: Adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet, 350: 1647-1654, 1997.
5. Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, Olmi P, Buonadonna A, Pignatti G, Barbieri E, Apice G, Zmerly H, Serraino D, Picci P: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian Randomized Cooperative Trial. J Clin Oncol, 19: 1238-1247, 2001.
6. Frustaci S, De Paoli A, Bidoli E, La Mura N, Berretta M, Buonadonna A, Boz G, Gherlinzoni F: Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology, 65: 80-84, 2003.
7. Frustaci S, Gherlinzoni F, De Paoli A, Pignatti G, Zmerly H, Azzarelli A, Comandone A, Buonadonna A, Olmi P, Ippolito V, Barbieri E, Apice G, Zakotnic B, Bacci G, Picci P: Preliminary results of an adjuvant randomized trial on high risk extremity soft tissue sarcomas (STS). The interim analysis. Proc Am Soc Clin Oncol, 16: 496a, Abstr 1785, 1997.
8. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Statis Assoc, 53: 457-481, 1958.
9. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer, 35: 1-39, 1977.
10. Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, Olmi P, Buonadonna A, Pignatti G, Barbieri E, Apice G, Zmerly H, Serraino D, Picci P: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian Randomized Cooperative Trial. Classic Paper and Current Comments, 7: 868-877, 2002.
11. Grobmyer SR, Maki RG, Demetri GD, Mazumdar M, Riedel E, Brennan MF, Singer S: Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol, 15: 1667-1672, 2004.
12. Gortzak E, Azzarelli A, Buesa J, Bramwell VHC, van Coevorden F, van Geel AN, Ezzat A, Santoro A, Oosterhuis JW, van Glabbeke M, Kirkpatrick A, Verweij J, the EORTC Soft Tissue Bone Sarcoma Group and the National Cancer Institute of Canada Clinical Trials Group/Canadian Sarcoma Group: A randomized phase II study on neo-adjuvant chemotherapy for "high-risk" adult sot tissue sarcoma. Eur J Cancer, 37: 1096-1103, 2001.
13. Bramwell V, Rouesse J, Steward W, Santoro A, Schraffordt-Koops H, Buesa J, Ruka W, Priario J, Wagener T, Burgers M, Van Unnik J, Contesso G, Thomas D, van Glabbeke M, Markham D, Pinedo H: Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma-reduced local recurrence but no improvement in survival: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol, 12: 1127-1149, 1994.
14. Antman KH: Adjuvant therapy of sarcomas of soft tissue. Semin Oncol, 24: 556-560, 1997.
15. Verweij J, Seynaeve C: The reason for confining the use of adjuvant chemotherapy in soft tissue sarcoma to the investigational setting. Semin Radiat Oncol, 9: 352-359, 1999.
16. Benjamin RS: Evidence for using adjuvant chemotherapy as standard treatment of soft tissue sarcoma. Semin Radiat Oncol, 9: 349-351, 1999.